Banning DTC Rx ads will not lower drug prices, says US Budget Office
This article was originally published in Scrip
Executive Summary
Banning direct-to-consumer advertising for new prescription medicines in the US is unlikely to help reduce consumer spending on drugs and could result in drug makers changing their marketing strategy by spending more on promoting their products to physicians, the Congressional Budget Office has stated in an issue brief.